Skip to NavigationSkip to content

MSD faces delay in C. diff drug approval as FDA requests more data

Published on 22/07/16 at 09:10am

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. diff infection treatment, bezlotoxumab, after the US Food and Drug Administration (FDA) requested more data from previously submitted clinical trials.

The additional data and analyses required will not set back the data for final date for approval by three months. The new prescription drug user fee act goal date has been set for October 23rd.

A meeting of the FDA’s antimicrobial drugs advisory committee had voted 10 to 5 to recommend the drug. Bezlotoxumab, a fully monoclonal lg61/kappa antibody, binds to and neutralises C difficile toxin B, which is likely by preventing it from binding to colonic cells and causing their inflammation.

MSD indicates that it looks forward to continuing to work with the FDA on the review for bezlotoxumab.

Sean Murray

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches